



Bayer-THU Collaboration

*2023 Call for Proposals for
Bayer Microfunding*



**Collaborate to Cure Hub China
Bayer Pharmaceuticals**

拜耳处方药中国合作创新中心

November 2023



RESTRICTED



Introduction

About Bayer Microfunding

To encourage research translation in drug discovery, Bayer will support Tsinghua in three **Microfunding** projects by an aggregate amount of up to 1.2 million CNY per year.

- // Each Microfunding project can be funded with up to a total of 400 kCNY for a maximum duration of two years
- // Microfunding projects will be research projects in Bayer's interested area, the projects will be solely conducted by Tsinghua investigators without involvement of Bayer. However, Bayer will try the best if any support is needed
- // The funding is to support Tsinghua Investigators to freely explore innovation translation, therefore, any project results deriving from a Microfunding project will solely be owned by Tsinghua

Who May Apply?

- // Eligible applicants need to be full-time employees of Tsinghua at the time of applying and receiving the fund
- // Working in the School of Life Sciences, School of Medicine, School of Pharmaceutical Sciences or Department of Chemistry, School of Information Science and Technology of Tsinghua
- // Independent of having a project with Bayer or not
- // **Must not** be healthcare professionals, or employed by a hospital due to international compliance requirements
- // Members of the Joint Steering Committee (JSC) may not apply for the fund
- // Having clear path of translating their research



Evaluation Process

- // The proposal will be evaluated based on the following considerations:
 1. Feasibility of translating your research to drug discovery
 2. Innovation and breakthrough potential in solving current unmet needs in diseases and drug discovery
 3. Research relevance to Bayer's areas of interest, including:
 - // Therapeutic areas in **Precision Oncology** (e.g. Precision molecular oncology, Targeted Radiotherapies, Next-gen Immunology, ADCs), **Precision cardiorenal diseases** (e.g. Heart Failure, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Chronic kidney disease, Alport, Autosomal dominant kidney disease, Lupus nephritis), **Neurology & Rare diseases** enabled by cell and gene therapy, and **Immunology & Inflammation** (e.g. Autoimmune disease).
 - // Novel technologies/platforms that enable target identification/drug discovery, specifically structural biology and biophysical methods (eg X-Ray, cryo-EM, AS MS, NMR ect), mRNA technology, disease models, organoids, iPSC-derived cell systems, organ on a chip, multi-omics techniques, bioinformatics, computational capabilities in protein design/protein engineering, biomarker research, nanomedicine, drug delivery, drug metabolism, pharmacokinetics, toxicology, chemistry related expertise in lead generation and optimization.
 - // Therapeutic modalities, e.g. peptide binders, protein degraders, molecular glue, modalities derived from conjugation platforms (antibody, peptide, glyco, radio labelling), RNA therapeutics, cell and gene
- // The proposal provided will be evaluated by Bayer scientific experts and the Joint Steering Committee (JSC) from both Bayer and Tsinghua University
- // Decision Letter will be sent out in **February 2024**. Bayer Alliance Manager will contact you regarding the decision and discuss the next steps.



Obligation

// **Use of Microfunding:**

- // The Microfunding shall be used exclusively for the performance of the Microfunding projects
- // Microfunding cannot be used to fund equipment and infrastructure.

// **Recipients of Bayer Microfunding Shall:**

- // Provide a mid-term and final report to Bayer for the project progress
- // Acknowledge funding by Bayer in their talks and publications in related areas of interest



Submission Process

// **Submit your proposal by Dec 20th, 2023**

// Please use the Application Form to submit an abstract of your research proposal or technology

// Please indicate in the abstract :

// What unmet need your research addresses?

// What is the advantage/differentiation of your solution?

// IP situation

// Path forward for the translation of your research

// **Please note that only non-confidential information should be provided**

// **Submit your proposal to Bayer and THU Alliance Managers**

Lidia Li, M.D. (李思妤)

Yuxin Li(李玉鑫)

Collaborate to Cure Hub China
Bayer Pharmaceuticals

General Office of Institute of Biomedicine
Tsinghua University

Tel: +010-85505499

Tel: +86 10 62781816

Mobile: +86 15120003110

Mobile: +86 13848615270

E-mail: lidia.li@bayer.com

E-mail: yuxin-li@mail.tsinghua.edu.cn



Thank you!

